[go: up one dir, main page]

CA2349837A1 - Traitement d'infections au moyen de proteines de fusion lysozyme - Google Patents

Traitement d'infections au moyen de proteines de fusion lysozyme Download PDF

Info

Publication number
CA2349837A1
CA2349837A1 CA002349837A CA2349837A CA2349837A1 CA 2349837 A1 CA2349837 A1 CA 2349837A1 CA 002349837 A CA002349837 A CA 002349837A CA 2349837 A CA2349837 A CA 2349837A CA 2349837 A1 CA2349837 A1 CA 2349837A1
Authority
CA
Canada
Prior art keywords
leu
lysozyme
ala
seq
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002349837A
Other languages
English (en)
Inventor
Timothy Edward Weaver
Henry Toyin Akinbi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/193,877 external-priority patent/US5993809A/en
Application filed by Individual filed Critical Individual
Publication of CA2349837A1 publication Critical patent/CA2349837A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une méthode et une composition destinées au traitement prophylactique et curatif d'infections bactériennes, en particulier au niveau des voies respiratoires. Une protéine de fusion de lysozyme et du propeptide C-terminal de la protéine tensioactive B (SP-B) avec les dix acides aminés précédents du peptide SP-B mature, ou le lysozyme recombinant seul, est administré à un patient via un support acceptable au plan pharmaceutique. La protéine de fusion seule ou le lysoszyme recombinant peut être sélectionné de manière à pouvoir être administré sur un site d'infection cible, tel que les poumons ou l'appareil gastro-intestinal. Ce procédé et cette composition permettent d'éviter certains problèmes associés à des traitements antibiotiques classiques, tels que la perte d'efficacité ou le développement de souches bactériennes résistant aux antibiotiques.
CA002349837A 1998-11-18 1999-11-18 Traitement d'infections au moyen de proteines de fusion lysozyme Abandoned CA2349837A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/193,877 US5993809A (en) 1998-11-18 1998-11-18 Lysozyme fusion proteins in infections
US09/193,877 1998-11-18
US44074299A 1999-11-16 1999-11-16
US09/440,742 1999-11-16
PCT/US1999/027403 WO2000029588A1 (fr) 1998-11-18 1999-11-18 Traitement d'infections au moyen de proteines de fusion lysozyme

Publications (1)

Publication Number Publication Date
CA2349837A1 true CA2349837A1 (fr) 2000-05-25

Family

ID=26889453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002349837A Abandoned CA2349837A1 (fr) 1998-11-18 1999-11-18 Traitement d'infections au moyen de proteines de fusion lysozyme

Country Status (6)

Country Link
EP (1) EP1129201A1 (fr)
JP (1) JP2002530083A (fr)
AU (1) AU759743B2 (fr)
BR (1) BR9915218A (fr)
CA (1) CA2349837A1 (fr)
WO (1) WO2000029588A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194570A1 (fr) 1999-06-23 2002-04-10 PPL Therapeutics (Scotland) Limited Proteines de fusion incorporant un lysozyme
EP1694848B1 (fr) 2003-12-18 2010-03-03 Justus-Liebig-Universität Giessen Nouveaux activateurs chimeres du plasminogene et leur utilisation a des fins pharmaceutiques
WO2005108563A2 (fr) * 2004-04-19 2005-11-17 University Of Chicago Proteine hydrolysant le peptidoglycane encodée par bacteriophage n4
AU2006207998A1 (en) 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. A method for characterizing the efficacy of an agent targeting a primary cystic fibrosis defect
EP2697387B1 (fr) * 2011-04-12 2021-09-15 Bactoclear Holdings PTE. LTD. Polypeptides chimères antibactériens
CN104817618B (zh) * 2014-01-30 2018-07-03 陈光健 寡肽cd01及其制备方法和应用
CN104817616A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd02及其制备方法和应用
CN114149986B (zh) * 2022-02-08 2022-05-06 中国科学院天津工业生物技术研究所 一种地衣芽孢杆菌溶菌酶突变体及其在虹鳟鱼保鲜中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3540075A1 (de) * 1985-11-12 1987-05-14 Boehringer Ingelheim Int Human-lysozym
DE3818094C1 (fr) * 1988-05-27 1989-07-20 Medichemie Ag, Ettingen, Ch
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances

Also Published As

Publication number Publication date
AU2345900A (en) 2000-06-05
JP2002530083A (ja) 2002-09-17
WO2000029588A1 (fr) 2000-05-25
BR9915218A (pt) 2001-07-31
EP1129201A1 (fr) 2001-09-05
AU759743B2 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
US5993809A (en) Lysozyme fusion proteins in infections
CA2181164C (fr) Procede et matieres de traitment d'infections bacteriennes a gram positif
EP0721501B1 (fr) Composition pharmaceutique comportant la phosphatase ou son derive
EP1659132A1 (fr) Fragments de BPI
AU2018384790C1 (en) Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
JP2002544759A (ja) カチオン性ペプチド単独、または抗生物質と組み合わせて用いて感染を処置するための組成物および方法
WO2003045976A2 (fr) Utilisation de proteines et peptides antimicrobiens dans le traitement de l'otite moyenne et de la sinusite paranasale
US7985729B2 (en) Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
AU759743B2 (en) Lysozyme fusion proteins in infections
Epaud et al. Bacterial killing is enhanced by exogenous administration of lysozyme in the lungs
US6767538B2 (en) Recombinant antibacterial group IIA phospholipase A2 and methods of use thereof
AU774207B2 (en) Recombinant SP-A for the treatment or prevention of pulmonary infection and inflammation
KR20210148320A (ko) 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체
CA2328134A1 (fr) Induction de proteines et de peptides antibiotiques au moyen de la proteine scd14/lait
US5770561A (en) Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US20200291082A1 (en) Prevention and treatment of graft-versus-host-disease with defensins
JP2017524000A (ja) 腹膜炎の治療のための組成物
EP1521770B1 (fr) Procede de production de protamine
Rae The effect of Mannheimia haemolytica pneumonia on antimicrobial peptide expression in ruminant lung

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued